Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31629694 | 0.84 | — | — | |
| SCHEMBL23086688 | 0.81 | DPP4 (0.36) | DPP4 | |
| SCHEMBL6201919 | 0.79 | ALDH1A1 (0.36) | DPP4 | |
| SCHEMBL23086702 | 0.79 | DPP4 (0.46) | DPP4 | |
| SCHEMBL21558089 | 0.78 | DPP4 (0.40) | DPP4 | |
| SCHEMBL19601432 | 0.77 | — | — | |
| SCHEMBL15960829 | 0.74 | DPP4 (0.35) | DPP4CA2 | |
| SCHEMBL15354776 | 0.72 | — | — | |
| SCHEMBL22262515 | 0.72 | DPP4 (0.33) | DPP4 | |
| SCHEMBL27281911 | 0.69 | DPP4 (0.41) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| EP-3792260-B1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO LTD (JP) | 2024-09-11 | — | — | EP | disclosed |
| CN-112368282-B | Azabenzimidazole compounds and medicaments | 日本新药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20210371412-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3792260-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-112368282-A | Azabenzimidazole compounds and pharmaceuticals | 日本新药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| WO-2019216294-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | 日本新薬株式会社 (JP) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371412-A1 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL | PAM, CHRM3, AZI2 | DPP4 419/4885CA2 91/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | DPP4 419/4885CA2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.